Skip to main content
SpringerLink
Log in

Prevalence and Disease Burden of Chronic Kidney Disease

  • Chapter
  • First Online:
Renal Fibrosis: Mechanisms and Therapies

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1165))

Abstract

Chronic kidney disease (CKD) has been recognized as a leading public health problem worldwide. The global estimated prevalence of CKD is 13.4% (11.7–15.1%), and patients with end-stage kidney disease (ESKD) needing renal replacement therapy is estimated between 4.902 and 7.083 million. Through its effect on cardiovascular risk and ESKD, CKD directly affects the global burden of morbidity and mortality worldwide. The global increase in this disease is mainly driven by the increase in the prevalence of diabetes mellitus, hypertension, obesity, and aging. But in some regions, other causes such as infection, herbal and environmental toxins are still common. The large number of deaths for poor access to renal replacement therapy in developing countries, and also large increase of patients with ESKD in future, will produce substantial financial burden for even the most wealthy countries. Cost-effectiveness of preventive strategies to reduce the disease burden should be evaluated in relation to the local economic development and resource. Strategies reducing the cardiovascular risk in CKD still need further evaluation in large trials especially including patients with advanced kidney disease or end-stage kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alves TP, Wang X, Wright JT Jr, Appel LJ, Greene T, Norris K et al (2010) Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol 21:1361–1369

    Article  CAS  Google Scholar 

  • Bamias G, Boletis J (2008) Balkan nephropathy: evolution of our knowledge. Am J Kidney Dis 52:606–616

    Article  Google Scholar 

  • Bello AK, Nwankwo E, El Nahas AM (2005) Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl 98:S11–S17

    Article  Google Scholar 

  • Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR (2003) Screening for proteinuria in us adults: a cost-effectiveness analysis. JAMA 290:3101–3114

    Article  CAS  Google Scholar 

  • Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ et al (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363:2287–2300

    Article  CAS  Google Scholar 

  • Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al (2007) Prevalence of chronic kidney disease in the united states. JAMA 298:2038–2047

    Article  CAS  Google Scholar 

  • Debelle FD, Vanherweghem JL, Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74:158–169

    Article  CAS  Google Scholar 

  • Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407

    Article  CAS  Google Scholar 

  • Fried LF (2010) Higher incidence of esrd than mortality in the AASK study. J Am Soc Nephrol 21:1244–1246

    Article  Google Scholar 

  • Gao B, Zhang L, Wang H, Zhao M (2014) Chinese cohort study of chronic kidney disease: design and methods. Chin Med J 127:2180–2185

    PubMed  Google Scholar 

  • GBD (2016) Causes of Death Collaborators (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1151–1210

    Google Scholar 

  • George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP (2017) Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health 2:e000256

    Article  Google Scholar 

  • Glassock RJ, Warnock DG, Delanaye P (2017) The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol 13:104–114

    Article  CAS  Google Scholar 

  • Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305

    Article  CAS  Google Scholar 

  • Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL et al (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442–1451

    Article  Google Scholar 

  • Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA et al (2017) Risks of adverse events in advanced CKD: the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 70:337–346

    Article  Google Scholar 

  • Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ et al (2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373:1009–1015

    Article  Google Scholar 

  • Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG et al (2011) Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: Improving global outcomes (KDIGO). Kidney Int 80:572–586

    Article  Google Scholar 

  • Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS ONE 11:e0158765

    Article  Google Scholar 

  • Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P et al (2010) A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 55:463–473

    Article  Google Scholar 

  • Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ et al (2013) Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 34:1807–1817

    Article  CAS  Google Scholar 

  • Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF et al (2015) Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in china: the CSPPT randomized clinical trial. JAMA 313:1325–1335

    Article  CAS  Google Scholar 

  • Imai E, Yamagata K, Iseki K, Iso H, Horio M, Mkino H et al (2007) Kidney disease screening program in japan: history, outcome, and perspectives. Clin J Am Soc Nephrol 2:1360–1366

    Article  Google Scholar 

  • Jain AK, McLeod I, Huo C, Cuerden MS, Akbari A, Tonelli M et al (2009) When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int 76:318–323

    Article  CAS  Google Scholar 

  • Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M et al (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382:1268–1277

    Article  CAS  Google Scholar 

  • James MT, Hemmelgarn BR, Tonelli M (2010) Early recognition and prevention of chronic kidney disease. Lancet 375:1296–1309

    Article  CAS  Google Scholar 

  • Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP et al (2010) Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 56:956–965

    Article  CAS  Google Scholar 

  • Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260–272

    Article  Google Scholar 

  • Jun M, Lv J, Perkovic V, Jardine MJ (2011) Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis 2:265–278

    Article  Google Scholar 

  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and managementof chronic kidney disease. Kidney Int Suppl 3:1–150

    Article  Google Scholar 

  • Kumaresan J, Seneviratne R (2017) Beginning of a journey: unraveling the mystery of chronic kidney disease of unknown aetiology (CKDU) in sri lanka. Global Health 13:43

    Article  Google Scholar 

  • Labarca J (2000) Antibiotic cycling tested in nosocomial infections. Lancet 355:992

    Article  CAS  Google Scholar 

  • Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254

    Article  CAS  Google Scholar 

  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

    Article  Google Scholar 

  • Lin CM, Yang MC, Hwang SJ, Sung JM (2013) Progression of stages 3b-5 chronic kidney disease–preliminary results of taiwan national pre-esrd disease management program in southern taiwan. J Formos Med Assoc 112:773–782

    Article  CAS  Google Scholar 

  • Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385:1975–1982

    Article  Google Scholar 

  • Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T et al (2013) Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185:949–957

    Article  Google Scholar 

  • Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF (2012) Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 12: CD004136

    Google Scholar 

  • Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J et al (2010) Population based screening for chronic kidney disease: cost effectiveness study. BMJ 341:c5869

    Article  Google Scholar 

  • Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081

    Article  Google Scholar 

  • Mazzuchi N, Schwedt E, Sola L, Gonzalez C, Ferreiro A (2006) Risk factors and prevention of end stage renal disease in uruguay. Ren Fail 28:617–625

    Article  Google Scholar 

  • McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM (2019) Projecting esrd incidence and prevalence in the united states through 2030. J Am Soc Nephrol 30:127–135

    Article  Google Scholar 

  • Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140:9–17

    Article  Google Scholar 

  • National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266

    Google Scholar 

  • Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657

    Article  CAS  Google Scholar 

  • Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A et al (2013) Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 347:f5680

    Article  CAS  Google Scholar 

  • Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX et al (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:23–33

    Article  Google Scholar 

  • Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572

    Article  CAS  Google Scholar 

  • Sharma SK, Ghimire A, Carminati S, Remuzzi G, Perico N (2014) Management of chronic kidney disease and its risk factors in eastern nepal. Lancet Glob Health 2:e506–e507

    Article  Google Scholar 

  • Steinberg D, Witztum JL (2002) Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105:2107–2111

    Article  Google Scholar 

  • Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E et al (2011) Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int 79:555–562

    Article  Google Scholar 

  • Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107:992–995

    Article  CAS  Google Scholar 

  • Wang ZJ, Harjai KJ, Shenoy C, Gao F, Shi DM, Liu YY et al (2013) Drug-eluting stents versus bare-metal stents in patients with decreased GFR: a meta-analysis. Am J Kidney Dis 62:711–721

    Article  CAS  Google Scholar 

  • Wang J, Zhang L, Tang SC, Kashihara N, Kim YS, Togtokh A et al (2018) Disease burden and challenges of chronic kidney disease in north and east asia. Kidney Int 94:22–25

    Article  Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334

    Article  CAS  Google Scholar 

  • Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248

    Article  CAS  Google Scholar 

  • Wei SY, Chang YY, Mau LW, Lin MY, Chiu HC, Tsai JC et al (2010) Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology (Carlton) 15:108–115

    Article  CAS  Google Scholar 

  • Wijkstrom J, Gonzalez-Quiroz M, Hernandez M, Trujillo Z, Hultenby K, Ring A et al (2017) Renal morphology, clinical findings, and progression rate in mesoamerican nephropathy. Am J Kidney Dis 69:626–636

    Article  Google Scholar 

  • Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al (2016) Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67:728–741

    Article  CAS  Google Scholar 

  • Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z et al (2016) Trends in chronic kidney disease in china. N Engl J Med 375:905–906

    Article  Google Scholar 

  • Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J et al (2012) Prevalence of chronic kidney disease in china: a cross-sectional survey. Lancet 379:815–822

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the National Key Research and Development Program of China (2018YFC1314004).

Author information

Authors and Affiliations

  1. Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China

    Ji-Cheng Lv & Lu-Xia Zhang

  2. KeyLaboratory of Renal Disease, Ministry of Health of China, Beijing, China

    Ji-Cheng Lv & Lu-Xia Zhang

  3. Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education of China, Beijing, China

    Ji-Cheng Lv & Lu-Xia Zhang

Authors
  1. Ji-Cheng Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu-Xia Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ji-Cheng Lv .

Editor information

Editors and Affiliations

  1. Zhongda Hospital, Southeast University School of Medicine, Southeast University, Nanjing, Jiangsu, China

    Bi-Cheng Liu

  2. Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong

    Hui-Yao Lan

  3. Zhongda Hospital, Southeast University School of Medicine, Southeast University, Nanjing, Jiangsu, China

    Lin-Li Lv

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lv, JC., Zhang, LX. (2019). Prevalence and Disease Burden of Chronic Kidney Disease. In: Liu, BC., Lan, HY., Lv, LL. (eds) Renal Fibrosis: Mechanisms and Therapies. Advances in Experimental Medicine and Biology, vol 1165. Springer, Singapore. https://doi.org/10.1007/978-981-13-8871-2_1

Download citation

Publish with us

Policies and ethics

Search

Navigation